ZA795932B - Use of compounds in the treatment of vasospastic or ischemic conditions - Google Patents

Use of compounds in the treatment of vasospastic or ischemic conditions

Info

Publication number
ZA795932B
ZA795932B ZA00795932A ZA795932A ZA795932B ZA 795932 B ZA795932 B ZA 795932B ZA 00795932 A ZA00795932 A ZA 00795932A ZA 795932 A ZA795932 A ZA 795932A ZA 795932 B ZA795932 B ZA 795932B
Authority
ZA
South Africa
Prior art keywords
vasospastic
compounds
treatment
ischemic conditions
ischemic
Prior art date
Application number
ZA00795932A
Other languages
English (en)
Inventor
F Dessy
J Birnbau
L Van Humbeeck
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of ZA795932B publication Critical patent/ZA795932B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0016—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing only hydroxy, etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0025—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing keto groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0033—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing sulfur

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA00795932A 1979-02-12 1979-11-05 Use of compounds in the treatment of vasospastic or ischemic conditions ZA795932B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/011,364 US4311707A (en) 1979-02-12 1979-02-12 Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions

Publications (1)

Publication Number Publication Date
ZA795932B true ZA795932B (en) 1981-03-25

Family

ID=21750072

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA00795932A ZA795932B (en) 1979-02-12 1979-11-05 Use of compounds in the treatment of vasospastic or ischemic conditions

Country Status (4)

Country Link
US (1) US4311707A (xx)
EP (1) EP0015658B1 (xx)
JP (1) JPS55111417A (xx)
ZA (1) ZA795932B (xx)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4322543A (en) * 1979-11-28 1982-03-30 G. D. Searle & Co. 4,5-Unsaturated prostanoic acid derivatives
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
JPS59128327A (ja) * 1983-01-10 1984-07-24 Teijin Ltd ７−チアプロスタグランジンｅ↓１類を有効成分とする経皮投与用薬剤
US4529812A (en) * 1983-02-02 1985-07-16 G. D. Searle & Co. 3-Oxaprostaglandins
US4883819A (en) * 1986-07-31 1989-11-28 The Trustees Of Columbia University In The City Of New York Use of A, B and C prostaglandins and derivatives thereof to treat ocular hypertension and glaucoma
FI872552A (fi) * 1986-06-09 1987-12-10 American Cyanamid Co Prostaglandinkomposition foer lokalt bruk.
FI872553A (fi) * 1986-06-09 1987-12-10 American Cyanamid Co Medium foer laekemedel foer lokalt bruk.
AU7875487A (en) * 1986-08-08 1988-02-24 Upjohn Company, The Methods, compositions and solutions for treating alopecia
US4822819A (en) * 1986-11-07 1989-04-18 Alcon Laboratories, Inc. Use of trimoprostil and derivatives in glaucoma therapy
US4822820A (en) * 1986-11-24 1989-04-18 Alcon Laboratories, Inc. Use of tri-methyl PG-F2 a and derivatives in glaucoma therapy
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5256652A (en) * 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
US4925873A (en) * 1988-09-01 1990-05-15 E. R. Squibb & Sons, Inc. Method of treating skin injuries using thromboxane A2 receptor antagonists
SE463851B (sv) * 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
FR2649613B1 (fr) * 1989-07-11 1991-09-27 Virag Ronald Medicament vaso-actif
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
US5175189A (en) * 1990-05-22 1992-12-29 K.K. Ueno Seiyaku Oyo Kenkyujo Treatment of ocular hypertension with a synergistic combination for ophthalmic use
DE69100171T2 (de) * 1990-05-22 1993-10-28 Ueno Seiyaku Oyo Kenkyujo Kk Synergistische Kombination zur ophthalmischen Verwendung.
US5962528A (en) * 1991-07-03 1999-10-05 Scott; Nathan Earl Prostaglandin E2 /F2α combination for treating impotence
US6291528B1 (en) 1991-07-03 2001-09-18 Nathan Earl Scott Prostaglandin E1/F2 in combination with prostaglandin F2α for enhancing female sexual arousal
US5981593A (en) * 1991-07-03 1999-11-09 Scott; Nathan Earl Prostaglandin E2 treatment of impotence
AU2300092A (en) * 1991-07-03 1993-02-11 Nathan E. Scott Prostaglandin e2 treatment of impotence
US5773457A (en) * 1995-02-15 1998-06-30 Cesar Roberto Dias Nahoum Compositions
BR9203277A (pt) * 1992-08-21 1994-03-01 Cesar Roberto Dias Nahoum Utilizaccao de drogas eretogenicas e respectivas metodologias de aplicacao
US5530027A (en) * 1993-02-03 1996-06-25 Teijin Limited External skin treatment agent composition containing prostacyclins as active ingredient
US5656663A (en) * 1993-02-03 1997-08-12 Teijin Limited External skin treatment agent composition containing isocarbacyclins as active ingredient
KR950000664A (ko) * 1993-06-14 1995-01-03 우에노 도시오 신규한 13,14-디히드로-피지에프 2 베타(PGF2β) 및 이의 이소프로필 에스테르
US5853755A (en) * 1993-07-28 1998-12-29 Pharmaderm Laboratories Ltd. Biphasic multilamellar lipid vesicles
SE9303444D0 (sv) * 1993-10-20 1993-10-20 Kabi Pharmacia Ab New use of prostaglandins
US5482039A (en) * 1994-03-25 1996-01-09 Vivus, Inc. Process for diagnosing erectile dysfunction, and related methods of treatment
TR199700930T2 (xx) * 1995-03-14 1998-07-21 Vivus Incorporated Ereksiyon bozuklu�unu �nlemek i�in y�ntem ve kit.
DE69823852T2 (de) 1997-02-04 2005-05-19 Johnstone, Murray A., Seattle Verfahren zur förderung des haarwuchses und entwicklung des haarsystems
US6103765A (en) * 1997-07-09 2000-08-15 Androsolutions, Inc. Methods for treating male erectile dysfunction
JP2001509480A (ja) 1997-07-09 2001-07-24 アンドロソリューションズ，インク． 男性勃起機能不全を治療するための改良された方法及び組成物
CA2314369A1 (en) * 1997-12-18 1999-06-24 Nathan Earl Scott Prostaglandin e2/f2.alpha. combination for treating impotence and enhancing sexual arousal
US6347243B1 (en) * 1998-03-05 2002-02-12 Advanced Monitors Corp. Probe cover for infrared thermometer
US6194433B1 (en) 1998-10-05 2001-02-27 Neal R. Cutler Sexual dysfunction in females
US6110489A (en) * 1998-05-01 2000-08-29 Cutler; Neal R. Use of quinolines and quinolones to treat male erectile dysfunction
US6187790B1 (en) 1999-03-04 2001-02-13 Neal R. Cutler Use of cilostazol for treatment of sexual dysfunction
US6132757A (en) * 1998-05-01 2000-10-17 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
US6426084B1 (en) * 2000-06-19 2002-07-30 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
US6132753A (en) * 1998-05-01 2000-10-17 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
US5942545A (en) * 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
US6825234B2 (en) 1998-12-10 2004-11-30 Nexmed (Holdings) , Inc. Compositions and methods for amelioration of human female sexual dysfunction
US20070191320A1 (en) * 1998-12-10 2007-08-16 Nexmed Holdings, Inc. Methods of treatment for female sexual arousal disorder
US6486207B2 (en) 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
HUP0200258A2 (hu) 1999-03-05 2002-05-29 The Procter & Gamble Co. C16-telítetlen FP-szelektív prosztaglandin analógok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
US6303135B1 (en) 1999-07-08 2001-10-16 Neal R. Cutler Use of quinolines and quinolones to treat male erectile dysfunction
US7105571B2 (en) * 2000-01-10 2006-09-12 Nexmed Holdings, Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
US6693135B2 (en) 2000-01-10 2004-02-17 Nexmed (Holdings) Incorporated Prostaglandin compositions and methods of treatment for male erectile dysfunction
US6323241B1 (en) 2000-01-10 2001-11-27 Nexmed (Holdings) Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020037914A1 (en) * 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US6562838B2 (en) * 2001-01-26 2003-05-13 R. T. Alamo Ventures I, L.L.C. Treatment of cardiovascular disease with quinolinone enantiomers
US9216183B2 (en) 2002-02-04 2015-12-22 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US8758733B2 (en) 2002-02-04 2014-06-24 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US7351404B2 (en) * 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US7041677B2 (en) * 2002-03-01 2006-05-09 R.T. Alamo Ventures I, Llc Use of monochloroflosequinan in the treatment of sexual dysfunction
JP2006522136A (ja) * 2003-04-02 2006-09-28 ネックスメド ホールディングス インコーポレイテッド プロスタグランジン組成物および血管痙攣の治療のためのその使用
GB0312552D0 (en) * 2003-06-02 2003-07-09 Nel Technologies Ltd Functional therapeutic corporeal and wound dressing heaters
US20080071247A1 (en) * 2006-09-18 2008-03-20 Dimera Incorporated Topical administration of a salt compound to facilitate venipuncture
US8722739B2 (en) * 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8623918B2 (en) 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US20100204335A1 (en) * 2008-12-01 2010-08-12 Allergan, Inc. Kit and composition for eyelash growth
US9149484B2 (en) 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
MX361709B (es) 2009-11-09 2018-12-07 Allergan Inc Composiciones y metodos para estimular el crecimiento del cabello.
IT1397867B1 (it) * 2010-02-03 2013-02-04 Brotzu Liposomi contenenti prostaglandina e1 (pge1), formulazioni che li contengono e loro uso
US8859616B2 (en) 2011-01-21 2014-10-14 Allergan, Inc. Compounds and methods for enhancing hair growth
JP2014510156A (ja) 2011-04-07 2014-04-24 ネクスメッド ホールディングス，インコーポレイテッド レイノー病を治療する方法および組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3551554A (en) * 1968-08-16 1970-12-29 Crown Zellerbach Corp Enhancing tissue penetration of physiologically active agents with dmso
FR2235678A1 (en) * 1973-07-02 1975-01-31 Merck & Co Inc Topical antipsoriasis agents - contg. prostaglandin E1 or E2
US4009282A (en) * 1973-12-17 1977-02-22 The Regents Of The University Of Michigan Treatment of proliferating skin diseases with prostaglandins
US4028396A (en) * 1975-07-02 1977-06-07 American Cyanamid Company 16,16-Spirocycloalkyl prostaglandin derivatives
US4158667A (en) * 1976-02-04 1979-06-19 The Upjohn Company 6-Keto PGF analogs
US4085272A (en) * 1977-03-30 1978-04-18 American Cyanamid Company 11-(2-Hydroxyethylthio)prostenoic acid E2 series derivatives
US4154954A (en) * 1977-03-30 1979-05-15 American Cyanamid Company 11-(2-Hydroxyethylthio) prostenoic acid E series derivatives
US4154959A (en) * 1977-03-30 1979-05-15 American Cyanamid Company 11-(2-Hydroxyethylthio)prostenoic acid E series derivatives
US4131738A (en) * 1977-07-05 1978-12-26 The Upjohn Company 6-Hydroxy-PGE1 compounds
DE2740953A1 (de) * 1977-09-12 1979-03-22 Thera Ges Fuer Patente Verwendung von prostaglandinen zur senkung des blutzuckerspiegels
CA1148149A (en) * 1977-12-08 1983-06-14 Allan Wissner Prostaglandin activity
JPS54104515A (en) * 1978-02-03 1979-08-16 Akebono Brake Ind Brake assembly parts for brake motor
US4254145A (en) * 1978-08-16 1981-03-03 American Cyanamid Company Topical application of prostaglandin hypotensive agents

Also Published As

Publication number Publication date
US4311707A (en) 1982-01-19
EP0015658A1 (en) 1980-09-17
JPS55111417A (en) 1980-08-28
EP0015658B1 (en) 1983-05-04

Similar Documents

Publication Publication Date Title
ZA795932B (en) Use of compounds in the treatment of vasospastic or ischemic conditions
GB2066310B (en) Hair-perming process and composition for use therein
EG14076A (en) 6-n-propyl 1-8-methoxymethyl or methylmercaptomethylergolines and related compounds
JPS5634621A (en) Dimethylsulfoxideecontaining treating composition
JPS5636412A (en) Methylsulfonylmethaneecontaining composition* its use and purification
GB2051071B (en) Arysulphonium salt mixtures
JPS565413A (en) Continuously releasing therapeutic composition
JPS55145181A (en) Corrosion controlling agent
GB2063288B (en) Liquid crystalline mixtures
JPS5676402A (en) Thermosettable composition
YU82683A (en) Rptary plough for holding and eaqualizing the inversion
DE3065077D1 (en) Composition and process for stabilizing soil
ZA805959B (en) 6-n-propyl-8a-methoxymethyl or methylmercatomethylergolines and related compounds
GB2048029B (en) Ozonizer
GB2014490A (en) Device for the manipulation of workpieces
DE3066550D1 (en) Process for the preparation of aryl-mono-,-di-and/or polyurethanes-
JPS55120514A (en) Composition for local treatment
JPS5684371A (en) Carbonnbonded magnesiaacarbon brick
GB2033377B (en) Cephem compounds and processes for preparation thereof
NZ190832A (en) D-2-azaergoline or 2-aza-(8 or 9)-ergolenes
JPS5688886A (en) Magnesiaacarbon brick
ZW13182A1 (en) Imidazolylpropionitriles process for the manufacture of these compounds and their use as biocidal agents
GB2034692B (en) Cephem compounds and processes for preparation thereof
JPS5716044A (en) Liquid stabilizing composition
GB1523705A (en) Process for the manufacture of iso-imides or mixtures of iso-imides and imides